Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.

Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES.

Circulation. 2003 Jun 17;107(23):2944-8. Epub 2003 May 27.

2.

Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease.

Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C.

Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1755-60. Epub 2004 Aug 19. Review.

3.

The ABCA1 transporter and ApoA-I: obligate or facultative partners?

Marguet D, Chimini G.

Trends Cardiovasc Med. 2002 Oct;12(7):294-8. Review.

PMID:
12458091
4.

Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium.

Andrews KL, Moore XL, Chin-Dusting JP.

Clin Exp Pharmacol Physiol. 2010 Jul;37(7):736-42. doi: 10.1111/j.1440-1681.2010.05387.x. Epub 2010 Mar 30. Review.

PMID:
20374256
5.

[Evaluation of vascular endothelial function].

Oshima T, Higashi Y, Ozono R, Nakano Y, Ishida M, Kambe M, Matsuura H, Kajiyama G.

Rinsho Byori. 2000 Sep;48(9):860-6. Review. Japanese.

PMID:
11051805
6.

High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein.

Calabresi L, Franceschini G.

Curr Opin Lipidol. 1997 Aug;8(4):219-24. Review.

PMID:
9253538
7.

Endothelium and the lipid metabolism: the current understanding.

Laroia ST, Ganti AK, Laroia AT, Tendulkar KK.

Int J Cardiol. 2003 Mar;88(1):1-9. Review.

PMID:
12659977
8.

Endothelial function in proteinuric renal disease.

Joles JA, Stroes ES, Rabelink TJ.

Kidney Int Suppl. 1999 Jul;71:S57-61. Review.

PMID:
10412739
9.

ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease.

Hong SH, Rhyne J, Zeller K, Miller M.

Atherosclerosis. 2002 Oct;164(2):245-50. Review.

PMID:
12204794
10.
11.

Reduced platelet count, but no major platelet function abnormalities, are associated with loss-of-function ATP-binding cassette-1 gene mutations.

Minuz P, Meneguzzi A, Femia EA, Fava C, Calabria S, Scavone M, Benati D, Poli G, Zancanaro C, Calandra S, Lucchi T, Cattaneo M.

Clin Sci (Lond). 2017 Jul 24;131(16):2095-2107. doi: 10.1042/CS20170195. Print 2017 Aug 15. Review.

PMID:
28634189
12.

[Tangier disease (familial high density lipoprotein deficiency)].

Tsukamoto T, Ishida M.

Ryoikibetsu Shokogun Shirizu. 1998;(22 Pt 3):554-6. Review. Japanese. No abstract available.

PMID:
9851216
13.

Potential mechanisms for cardiovascular protective effect of ethanol.

Redmond EM, Sitzmann JV, Cahill PA.

Acta Pharmacol Sin. 2000 May;21(5):385-90. Review.

14.

HDL and endothelial protection.

Tran-Dinh A, Diallo D, Delbosc S, Varela-Perez LM, Dang QB, Lapergue B, Burillo E, Michel JB, Levoye A, Martin-Ventura JL, Meilhac O.

Br J Pharmacol. 2013 Jun;169(3):493-511. doi: 10.1111/bph.12174. Review.

15.

The role of HDL in reverse cholesterol transport and its disturbances in Tangier disease and HDL deficiency with xanthomas.

Schmitz G, BrĂ¼ning T, Williamson E, Nowicka G.

Eur Heart J. 1990 Aug;11 Suppl E:197-211. Review. No abstract available.

PMID:
2226526
16.

[Tangier disease].

Matsunaga A, Sasaki J.

Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):20-3. Review. Japanese. No abstract available.

PMID:
9644997
17.

Non-clinical development of CER-001.

Barbaras R.

Front Pharmacol. 2015 Oct 6;6:220. doi: 10.3389/fphar.2015.00220. eCollection 2015. Review.

18.

Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease.

Kingwell BA, Chapman MJ.

Circulation. 2013 Sep 3;128(10):1112-21. doi: 10.1161/CIRCULATIONAHA.113.002683. Review. No abstract available.

Supplemental Content

Support Center